Australia markets close in 2 hours 38 minutes

ABBV Jan 2025 110.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
64.810.00 (0.00%)
As of 02:38PM EST. Market open.
Full screen
Previous close64.81
Open64.81
Bid64.95
Ask68.60
Strike110.00
Expiry date2025-01-17
Day's range64.81 - 64.81
Contract rangeN/A
Volume9
Open interest175
  • Reuters

    UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports

    AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.

  • Bloomberg

    AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

    (Bloomberg) -- Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.Most Read from BloombergNvidia Surges After AI Boom Shows No Signs of Letting UpTech Up in Late Hours on Nvidia’s Bullish Outlook: Markets WrapBiden Touts $1.2 Billion in Student Loan Relief With Eye to 2024Your 401(k) Will Be Gone Within a DecadeChina Tig

  • Zacks

    AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.